Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)

The maintenance with Iopinavir/ritonavir monotherapy vs. continuing Iopinavir/ritonavir and 2 nucleosides in Human Immunodeficiency Virus (HIV)-infected patients with suppresses HIV replication is evaluated. The results reveal that the failure of Iopinavir/ritronavir monotherapy are not associated with the development of primary resistance mutations in the protease gene and could be successfully reinduced adding back prior nucleosides.